Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-jcwnq Total loading time: 0.309 Render date: 2021-10-24T10:39:29.173Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

17 - MRI as a tool in stroke drug development

Published online by Cambridge University Press:  26 August 2009

Stephen Davis
Affiliation:
Royal Melbourne Hospital and University of Melbourne
Marc Fisher
Affiliation:
National Institute of Mental Health, Bethesda, Maryland
Steven Warach
Affiliation:
National Institutes of Health, Baltimore
Get access

Summary

The disappointingly slow progress in developing effective therapies for ischemic stroke, along with the clinical development of diffusion and perfusion MRI, has led to a re-evaluation of the strategies for the design of stroke clinical trials. Rapid, early MRI has been proposed and begun to be used in stroke trials as a means of optimizing patient selection and as a direct measure of the effect of treatments on cerebral infarction, as the marker of therapeutic response.

The need for a more rationale approach to clinical development of stroke therapeutics

The first and only success in developing an approved therapy culminated in the pivotal trials of intravenous recombinant tissue plasminogen activator (t-PA), reported in 1995 and leading to regulatory approval in 1996. The key insight of the designers of these trials was optimizing the sample with regard to time to treatment, requiring patients to be treated within three hours from onset of symptoms. They recognized that very early stroke treatment would be more effective and that the earliest cases are most likely to still have the causative arterial occlusions, which may spontaneously lyse at later times. Thus, patients were included across the broad range of clinical features, and selection of patients by imaging confirmation of the diagnosis or pathologic features most amenable to the treatment was not necessary to prove the efficacy of intravenous t-PA for the less than 3 hours' time window.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×